(19)

(11)

EP 4 376 834 A1

(12)

(43) Date of publication: 05.06.2024 Bulletin 2024/23 (21) Application number: 22850031.0 (22) Date of filing: 14.04.2022

(51) International Patent Classification (IPC):  A61K 31/404(2006.01) A61P 31/14(2006.01) C07D 487/10(2006.01) (52) Cooperative Patent Classification (CPC): C07D 487/10; A61P 31/14; C07D 487/20; C07D 519/00 (86) International application number: PCT/US2022/024772 (87) International publication number: WO 2023/009187 (02.02.2023 Gazette 2023/05)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 29.07.2021 US 202163227206 P 20.09.2021 US 202117479248 28.03.2022 US 202263324367 P (71) Applicant: Enanta Pharmaceuticals, Inc. Watertown, MA 02472 (US)

(72) Inventors: SHEN, Ruichao Belmont, MA 02478 (US) HE, Yong Lexington, MA 02420 (US) XING, Xuechao Wilmington, MA 01887 (US) RHODES, Matthew, C. Boston, MA 02134 (US) PANARESE, Joseph, D. Newton, MA 02460 (US) BARTLETT, Samuel Brighton, MA 02135 (US) LI, Wei Lexington, MA 02421 (US) CAO, Hui Belmont, MA 02478 (US) ZHANG, Jiajun Cambridge, MA 02139 (US) PENG, Xiaowen Sudbury, MA 01776 (US) WANG, Guoqiang Belmont, MA 02478 (US) OR, Yat, Sun Waltham, MA 02452 (US) (74) Representative: Latscha Schöllhorn Partner AG  Grellingerstrasse 60 4052 Basel 4052 Basel (CH)